Dipeptidyl-Peptidase-4 Inhibitors Shown Not to Increase Short-Term Risk of Pancreatic Cancer
the Cancer Therapy Advisor take:
According to a new study published in the journal Diabetes, Obesity and Metabolism, researchers at the University of North Carolina Gillings School of Public Health and the University of North Carolina School of Medicine in Chapel Hill, North Carolina, have found that dipeptidyl-peptidase-4 (DPP-4) inhibitors do not increase the short-term risk of developing pancreatic cancer.
Researchers identified patients that had taken DPP-4 inhibitors, as well as sulfonylureas (SUs) and thiazolidinediones (TZDs), three classes of medications used to treat type 2 diabetes. Then, researchers compared the rates of developing pancreatic cancer and found no increased risk among those that took DPP-4 inhibitors compared with those that took SUs or TZDs.
DPP-4 inhibitors, which include commonly used medications like sitagliptan, saxagliptan, and linagliptan, work by increasing incretin levels, resulting in decreased glucagon release, increased insulin secretion, decreased gastric emptying, and decreased glucose levels. In 2013, a study found that DPP-4 inhibitors caused changes to the pancreases of rats that may lead to pancreatic cancer. Though this new study was short, researchers say that it should reassure older patients that DPP-4 inhibitors are safe to treat their diabetes.
DPP-4 inhibitors do not increase the short-term risk of developing pancreatic cancer.
Researchers at the UNC Gillings School of Global Public Health and the UNC School of Medicine have found that a popular class of diabetes medications called DPP-4 inhibitors does not increase the short-term risk of pancreatic cancer, as was previously reported by other researchers.
"Our research shows that short-term use of DPP-4 inhibitors in older diabetes patients does not increase their risk for pancreatic cancer," said John Buse, MD, PhD, director of the Diabetes Care Center at UNC and co-author of the paper in the current issue of the journal Diabetes, Obesity and Metabolism. "However, we just cannot address the long-term safety, yet. There are just not enough people who have taken the drug for many years."
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Combination Abiraterone Acetate, Radium-223 Not Recommended in CRPC With Bone Mets
- Brigatinib Found More Effective for ALK-positive NSCLC Brain Mets Compared With Crizotinib
- Higher Baseline AFP Linked to Greater Benefit With Cabozantinib in Hepatocellular Carcinoma
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- A Big BiTE: Tetravalent BiTE Highly Potent in HER2-positive Breast Cancer Models